8:25 am
Chair’s Opening Remarks
Recognizing the Clinical Impact of Myeloid Targeted Therapies to Benchmark Efficacy & Safety
8:30 am Industry Leaders’ Fireside Chat: Reviewing the Current Landscape & Future Potential of the Myeloid
Synopsis
- Assessing the target landscape of myeloid-directed therapies to identify advances in well-known antigens and uncover the prospects of novel targets
- Discussing the top challenges developers face and novel approaches to tackles these
- Expressing opinions on combination therapies and the opportunity they create for myeloid-directed therapies
- Securing safety and efficacy validation from clinical assets to reaffirm the potential of targeting the myeloid compartment
9:30 am Phase 1a Results of PY159 & PY314
Synopsis
- Evaluating safety and tolerability
- Determining PK and the recommended dose for expansion
- Outlining next steps and future outlook
10:00 am Alligator’s CD40 Program
Synopsis
Targeting CD40 on Myeloid Cells to Reverse the Suppressive Tumor Microenvironment & Enhance T Cell Priming.
- Mitazalimab, a second generation CD40 agonistic monoclonal antibody is currently under investigation in a phase 2 study in pancreatic cancer patients and have shown very promising Interim Results with ORR>50%
- Preclinical data as well as clinical efficacy and pharmacodynamic biomarker data from the interim readout will be presented
- Further, preclinical in vivo and vitro data on ATOR-4066, a third generation CD40 agonist, and a CD40xCEA bispecific antibody developed within the Neo-X-Prime™ platform will be presented
10:30 am
Morning Refreshment Break & Speed Networking
Harnessing the Power of Combination Therapies to Prime the Microenvironment & Prevent Therapy Resistance
11:30 am Targeting Tumor Microenvironment for Next Generation Cancer Immunotherapies
Synopsis
- A bispecific antibody targeting CD39/TGF-β to create an immune-friendly tumor microenvironment. Expected single agent activity in solid tumors
- The bispecific macrophage engager (BiME®) brings and activates macrophages in the tumor proximity for a kill
12:00 pm Round Table: Designing Rational Combinations to Improve Therapy Efficacy without Affecting Toxicity
Synopsis
- Discussing best-practice to choose a targeted therapy to prime the tumor microenvironment and alleviate immunosuppression
- Evaluating agents to activate the adaptive immune system and trigger tumor cell elimination
- How can you determine the in vivo activity caused by each agent to demonstrate the enhanced impact of the combination approach?
12:30 pm
Lunch Break & Networking
1:30 pm First-In-Human Phase 1 Trial of IO-108, an Antagonist Antibody Targeting LILRB2 (ILT4), as Monotherapy & in Combination with Pembrolizumab in Adult Patients with Advanced Relapsed or Refractory Solid Tumors: Dose Escalation Data (NCT05054348)
Synopsis
- IO-108 was well tolerated up to 1800 mg, both in monotherapy and in combination with pembrolizumab
- Durable responses were observed in patients treated with IO-108 monotherapy and with IO-108 in combination with pembrolizumab
- The encouraging data support further clinical development of IO-108 in patients with various advanced solid tumors
2:00 pm Preclinical Development of AB598, a CD39 Inhibitory Antibody, to Promote Anti-Tumor Immunity
Synopsis
- AB598 is a potent and specific molecule capable of inhibiting CD39 in the TME
- AB598 can activate myeloid cells by increasing the reservoir of extracellular ATP
- Combining AB598 with chemotherapy in solid tumors is a promising approach for immuno-oncology
2:30 pm
Afternoon Break & Refreshments
Utilizing Cell-Based & Direct Cell-Targeting Approaches to Drive a Strong Anti-Tumor Response
3:00 pm Employing a CAR-Macrophage to Mediate Directed Tumor Cell Killing
Synopsis
- Engineering a CAR to boost specificity of macrophage cell therapy and mediate tumor cell phagocytosis
- Retaining a pro-inflammatory cell phenotype to maintain tumor killing function
- Boosting scalable manufacturing of autologous therapies to generate large numbers of targeted cells
3:30 pm ACTM-838, a Novel Cell-Based Immunotherapy Enables Systemic Delivery with Tumor-Specific Effects & Generates Durable Anti-Tumor Immunity
Synopsis
- STACT (S. Typhimurium-Attenuated Cancer Therapy) is a novel immunotherapeutic modality that can be systemically delivered with tumor-specific effects
- Characteristics include: enriches in solid tumors, not healthy tissue, tumor-specific payload delivery and multiplexed targeting in a single therapy
- ACTM-838 is Actym’s lead development candidate, a STACT that encodes engineered IL15 + eSTING payloads. ACTM-838 has potent single agent activity against multiple tumor models after IV dosing with synergy when combined with PD-1. ACTM-838 induces profound myeloid and broad immune reprogramming of the TME leading to anti-tumor immunological memory
4:00 pm Targeting Myeloid Derived Suppressor Cells (MDSCs) to Reshape the Immunosuppressive Microenvironment
Synopsis
- Clarifying the various mechanisms of suppression by MDSCs to distinguish pathways for intervention Development of OR2805, a clinical stage anti-CD163 antibody derived from an Elite Responder to checkpoint inhibitor therapy that relieves immunosuppression caused by macrophages
- Discovery of anti-LILRB2/ILT4 lead antibody OR502 that rescues T cells from macrophage-mediated suppression
4:30 pm Poster Session
Synopsis
This is the perfect opportunity to contribute to the conversation and share your cutting-edge research with this community while discovering exciting work carried out by your peers. Get in touch if you would like to be involved!